Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Cell & gene therapy, Neuroscience

The Secret is the Secretions

Ophthalmology is full of advances, but sometimes the field is very conservative. Look at the extended-release drug delivery systems that have made it to market: Vitrasert, Ozurdex, Retisert, Iluvien. New drug delivery technology, but really old drugs (ganciclovir, dexamethasone, and fluocinolone acetonide). I think it’s clear that the use of steroids for the treatment of retinal disease will diminish – their drawbacks and side-effects are well-known, and there’s (hopefully) better therapeutic approaches on the horizon.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Nicolas Sohl

Nicolas Sohl is CEO and co-Founder of Cell Care Therapeutics.

Related Solutions

Research Field Drug discovery

Dental Curing Lights: Clinical Reality

| Contributed by Ocean Optics

Research Field Genetics

Measuring DNA Absorbance with the STS-UV

| Contributed by Ocean Optics

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register